AbbVie

Open: 150.84 Close: 152.98 Change: 2.14

Try an AI to get informed about investing in AbbVie.

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Abbvie, share, earnings, first, year, Thursday, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

Revenue at North Chicago-based Abbvie dove by nearly 10% during the first few months of this year. AbbVie expects full-year earnings in the range of $10.72 to $11.12 per share.

Today's News

AbbVie expects full-year earnings in the range of $10.72 to $11.12 per share. Revenue at North Chicago-based Abbvie dove by nearly 10% during the first few months of this year. AbbVie turns 10 this year, and a new corporate campaign is tapping employees to highlight the decade of accomplishments. The campaign includes real employees from around the world talking about why they like working there, what theyre proud of. AbbVie will announce its first-quarter 2023 financial results on Thursday, April 27, 2023, before the market opens. Abbvie has been a strong performer since its split from Abbott Labs, and its trying hard to keep the momentum going. AbbVie expects full-year earnings in the range of $10.72 to $11.12 per share. The company also won two other awards, the WorldStar Award 2016 for its syringe closure system Vetter-Ject, and the 2016 CMO Leadership Award. AbbVie stock crumbled Thursday after the first biosimilar to launch in the U.S. Humira Downfall Is Swift As Biosimilars Hammer Away At Sales. The company reported adjusted earnings of $2.46 per share and $12.23 billion. Abbvie Inc. reports 9.7% fall in global net revenues for q1 2022. AbbVies immunology portfolio registered global net revenue of $5.58bn during Q1 2023. AbbVie stock sinks 5.1% premarket after Q1 profit missed expectations. European Commission (EC) approved Rinvoq as the first oral Janus Kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active Crohns disease. AbbVie raising its adjusted diluted EPS guidance for the full year 2023 from $10.62 - $11.02 to $10.72 -  $11.12. The CRL did not request that Abbvie conduct additional efficacy and safety trials. AbbVie missed quarterly revenue estimates for its newer treatments. The drugmakers shares plunged last Thursday after Abbvie announced its first-quarter results. The company is betting on newer drugs Skyrizi for psoriasis and related conditions.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

Are looking for the most relevant information about AbbVie? Investor spend a lot of time searching for information to make investment decisions in AbbVie. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Abbvie, share, earnings, first, year, Thursday, and the most common words in the summary are: abbvie, stock, news, market, abbv, new, earnings, . One of the sentences in the summary was: AbbVie expects full-year earnings in the range of $10.72 to $11.12 per share.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #news #market #abbv #new #earnings.